Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M9EV
|
|||
| Drug Name |
NBTX-001
|
|||
| Indication | Post-traumatic stress disorder [ICD-11: 6B40; ICD-10: F43.1, F62.0; ICD-9: 309.81] | Phase 2/3 | [1] | |
| Panic disorder [ICD-11: 6B01; ICD-10: F41.0; ICD-9: 300.01, 300.21] | Phase 1 | [2] | ||
| Company |
Nobilis Therapeutics Portland, OR
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03635827) Xenon Inhalation for Treatment of Posttraumatic Stress Disorder. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.